Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) released its inaugural Monthly Return for the period ended 30 June 2026, confirming that no changes occurred in either its authorised or issued share capital during its first trading day on the Hong Kong Main Board.

Total Share Capital • Authorised/registered share capital stood at 308.38 million shares with a par value of RMB 1 each. • H-shares accounted for 307.09 million shares, while domestic shares totalled 1.29 million shares.

Issued Shares and Treasury Shares • Issued H-shares remained unchanged at 307.09 million; no treasury shares were held. • Domestic issued shares were steady at 1.29 million. • No share repurchases, cancellations, or issuances were reported.

Public Float • The company confirmed compliance with the Main Board’s minimum 25% public float requirement as of 30 June 2026.

Capital Instruments • The return recorded no outstanding share options, warrants, convertibles, or other equity-linked agreements.

Governance The filing was authorised by Chairperson and Executive Director Jing Yue, affirming adherence to all Hong Kong listing rules and regulatory obligations.